Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
5.60
USD
+0.09
(+1.54%)
Delcath Systems, Inc.
DCTH:UA
(NYSE MKT LLC)
Recent
price
5.60
P/E
ratio
-1.55
div
yld
- -
ROIC.AI
-3.61EPS Dil.
-1.55P/E
110.26MMarket Cap
Legends:
Stock price
0.80
Beta (1.0 Market)
% total return 05/09
Stock
S&P500
YTD
-43.09
- -
3Y
-67.83
- -
5Y
-96.14
- -
Capital Structure
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
4
5
8
LT Borrowings
6
5
2
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
15
20
Market Capitalization
58
89
80
Working Capital
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
29
19
46
Cash, Cash Equivalents & STI
24
15
40
Accounts Receivable, Net
0
0
0
Inventories
2
2
3
Total Current Liabilities
13
11
14
Payables & Accruals
8
5
4
ST Debt
4
5
8
Deferred Revenue
- -
- -
- -
Growth Rates
FRC
•
in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
0.00%
8.33%
-25.00%
Net Income, GAAP
-17.95%
-21.38%
-42.31%
Free Cash Flow
2.64%
-11.66%
-8.70%
Total Cash Common Dividend
- -
- -
- -
Total Equity
-255.32%
-440.42%
-150.00%
Quarterly Revenue
FRC
•
in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
0
1
1
2
4
2022
0
1
1
1
3
2023
1
0
0
- -
- -
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
89.66
60.77
0.57
0.50
0.31
0.17
Revenue per ShareRevenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-505.84
-341.50
-8.34
-3.59
-4.12
-3.61
Basic EPS, GAAPBasic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-389.68
-912.08
-8.16
-3.18
-2.84
-2.35
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-22,930.07
-5,539.85
-65.92
-53.23
-45.52
-25.08
Book Value per ShareBook Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-995.93
-94.88
3.68
1.51
-0.58
1.26
Tangible Book Value per ShareTangible Book Value per Share